Fintech PR

Novo Holdings Venture Investments 2023 Newsletter: A record year advancing innovative therapies for patients

Published

9 months ago

March 5, 2024

18 new portfolio investments
Five portfolio companies acquired
$766 million invested and committed
$600 million of cash exit proceeds

COPENHAGEN, Denmark and LONDON and SAN FRANCISCO, March 5, 2024 /PRNewswire/ — The Novo Holdings Venture Investments team today published its review of 2023 – a record year advancing innovative therapies for patients.

The Novo Holdings Venture Investments team is one of the largest and most active international life science venture investors, with a track record of nearly 25 years investing in novel therapies. The Venture Investments portfolio includes both private and publicly traded investments in the biotech, medtech and digital health sectors, and spans early-stage, translatable science through commercial stage products.

Scott Beardsley, Managing Partner and Head of Venture Investments, said: “2023 was another very productive year for the Novo Holdings Venture Investments Team. We added a record number of new portfolio investments and returned significant capital to the Foundation.

“As we approach our 25-year anniversary as an investor in the life sciences industry, we see tremendous opportunity ahead. In 2023, we continued to develop our team, invested in new opportunities, and remained a preferred partner and investor for life sciences globally.”

For more information and to read the review in full, please visit link on our website.

About Novo Holdings

Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.

Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novozymes A/S and manages an investment portfolio, with a long-term return perspective. Novo Holdings is a world-leading life sciences investor. Through its Seeds, Venture, Growth, and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development.

About Novo Holdings A/S

Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation’s assets.

Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets. Further information: www.novoholdings.dk.